Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="http://www.bloodjournal.org/content/bloodjournal/132/16/1703/F1.medium.gif" width="440" height="392"/>Download figureOpen in new tabDownload powerpoint - - Mole...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Thol, Felicitas (VerfasserIn) , Schlenk, Richard Friedrich (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 6, 2018
In: Blood
Year: 2018, Jahrgang: 132, Heft: 16, Pages: 1703-1713
ISSN:1528-0020
DOI:10.1182/blood-2018-02-829911
Online-Zugang:Verlag, Volltext: https://doi.org/10.1182/blood-2018-02-829911
Verlag, Volltext: http://www.bloodjournal.org/content/132/16/1703
Volltext
Verfasserangaben:Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian Kandziora, Lothar Hambach, Michael Stadler, Christian Koenecke, Madita Flintrop, Mira Pankratz, Martin Wichmann, Blerina Neziri, Konstantin Büttner, Bennet Heida, Sabrina Klesse, Anuhar Chaturvedi, Arnold Kloos, Gudrun Göhring, Brigitte Schlegelberger, Verena I. Gaidzik, Lars Bullinger, Walter Fiedler, Albert Heim, Iyas Hamwi, Matthias Eder, Jürgen Krauter, Richard F. Schlenk, Peter Paschka, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, and Michael Heuser

MARC

LEADER 00000caa a2200000 c 4500
001 1670626970
003 DE-627
005 20230426082359.0
007 cr uuu---uuuuu
008 190806s2018 xx |||||o 00| ||eng c
024 7 |a 10.1182/blood-2018-02-829911  |2 doi 
035 |a (DE-627)1670626970 
035 |a (DE-599)KXP1670626970 
035 |a (OCoLC)1341235381 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Thol, Felicitas  |d 1977-  |e VerfasserIn  |0 (DE-588)129633984  |0 (DE-627)475217403  |0 (DE-576)297759329  |4 aut 
245 1 0 |a Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML  |c Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian Kandziora, Lothar Hambach, Michael Stadler, Christian Koenecke, Madita Flintrop, Mira Pankratz, Martin Wichmann, Blerina Neziri, Konstantin Büttner, Bennet Heida, Sabrina Klesse, Anuhar Chaturvedi, Arnold Kloos, Gudrun Göhring, Brigitte Schlegelberger, Verena I. Gaidzik, Lars Bullinger, Walter Fiedler, Albert Heim, Iyas Hamwi, Matthias Eder, Jürgen Krauter, Richard F. Schlenk, Peter Paschka, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, and Michael Heuser 
264 1 |c September 6, 2018 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.08.2019 
520 |a Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="http://www.bloodjournal.org/content/bloodjournal/132/16/1703/F1.medium.gif" width="440" height="392"/>Download figureOpen in new tabDownload powerpoint - - Molecular measurable residual disease (MRD) assessment is not established in approximately 60% of acute myeloid leukemia (AML) patients because of the lack of suitable markers for quantitative real-time polymerase chain reaction. To overcome this limitation, we established an error-corrected next-generation sequencing (NGS) MRD approach that can be applied to any somatic gene mutation. The clinical significance of this approach was evaluated in 116 AML patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) in complete morphologic remission (CR). Targeted resequencing at the time of diagnosis identified a suitable mutation in 93% of the patients, covering 24 different genes. MRD was measured in CR samples from peripheral blood or bone marrow before alloHCT and identified 12 patients with persistence of an ancestral clone (variant allele frequency [VAF] >5%). The remaining 96 patients formed the final cohort of which 45% were MRD+ (median VAF, 0.33%; range, 0.016%-4.91%). In competing risk analysis, cumulative incidence of relapse (CIR) was higher in MRD+ than in MRD− patients (hazard ratio [HR], 5.58; P < .001; 5-year CIR, 66% vs 17%), whereas nonrelapse mortality was not significantly different (HR, 0.60; P = .47). In multivariate analysis, MRD positivity was an independent negative predictor of CIR (HR, 5.68; P < .001), in addition to FLT3-ITD and NPM1 mutation status at the time of diagnosis, and of overall survival (HR, 3.0; P = .004), in addition to conditioning regimen and TP53 and KRAS mutation status. In conclusion, NGS-based MRD is widely applicable to AML patients, is highly predictive of relapse and survival, and may help refine transplantation and posttransplantation management in AML patients. 
700 1 |a Schlenk, Richard Friedrich  |d 1965-  |e VerfasserIn  |0 (DE-588)129025380  |0 (DE-627)387778004  |0 (DE-576)297454102  |4 aut 
773 0 8 |i Enthalten in  |t Blood  |d Washington, DC : American Society of Hematology, 1946  |g 132(2018), 16, Seite 1703-1713  |h Online-Ressource  |w (DE-627)266886647  |w (DE-600)1468538-3  |w (DE-576)075961938  |x 1528-0020  |7 nnas  |a Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML 
773 1 8 |g volume:132  |g year:2018  |g number:16  |g pages:1703-1713  |g extent:11  |a Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML 
856 4 0 |u https://doi.org/10.1182/blood-2018-02-829911  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.bloodjournal.org/content/132/16/1703  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190806 
993 |a Article 
994 |a 2018 
998 |g 129025380  |a Schlenk, Richard Friedrich  |m 129025380:Schlenk, Richard Friedrich  |d 910000  |d 910100  |e 910000PS129025380  |e 910100PS129025380  |k 0/910000/  |k 1/910000/910100/  |p 28 
999 |a KXP-PPN1670626970  |e 3504245581 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"September 6, 2018","dateIssuedKey":"2018"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLBlood","corporate":[{"display":"American Society of Hematology","role":"isb"}],"titleAlt":[{"title":"Blood online"}],"part":{"volume":"132","year":"2018","text":"132(2018), 16, Seite 1703-1713","pages":"1703-1713","extent":"11","issue":"16"},"language":["eng"],"note":["Gesehen am 21.04.2023"],"pubHistory":["1.1946 -"],"id":{"eki":["266886647"],"issn":["1528-0020"],"zdb":["1468538-3"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"journal of the American Society of Hematology","title":"Blood","title_sort":"Blood"}],"origin":[{"dateIssuedKey":"1946","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedDisp":"1946-"}],"recId":"266886647"}],"physDesc":[{"extent":"11 S."}],"id":{"doi":["10.1182/blood-2018-02-829911"],"eki":["1670626970"]},"title":[{"title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","title_sort":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 06.08.2019"],"recId":"1670626970","person":[{"given":"Felicitas","display":"Thol, Felicitas","role":"aut","family":"Thol"},{"given":"Richard Friedrich","display":"Schlenk, Richard Friedrich","family":"Schlenk","role":"aut"}],"language":["eng"],"name":{"displayForm":["Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian Kandziora, Lothar Hambach, Michael Stadler, Christian Koenecke, Madita Flintrop, Mira Pankratz, Martin Wichmann, Blerina Neziri, Konstantin Büttner, Bennet Heida, Sabrina Klesse, Anuhar Chaturvedi, Arnold Kloos, Gudrun Göhring, Brigitte Schlegelberger, Verena I. Gaidzik, Lars Bullinger, Walter Fiedler, Albert Heim, Iyas Hamwi, Matthias Eder, Jürgen Krauter, Richard F. Schlenk, Peter Paschka, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, and Michael Heuser"]}} 
SRT |a THOLFELICIMEASURABLE6201